Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Tom Caruthers who wrote (719)	5/5/1998 4:57:00 PM
From: Phil Cressman	Read Replies (2) \| Respond to of 2135

Having lost my wife to cancer a few years ago I am hoping as much as anyone for EntreMed or one of the many other new research programs to come up with improved treatments or cures. My investments over the past two years have, unfortunately, reflected my interest in this field. I have found that it is not a good idea to let your emotions control your investment decisions! EntreMed has a valid line of investigation and animal studies have shown results at least as good as other investigational studies by competitors! Keep in mind however, that this company is a long, long way from human studies and hopefully approval for use. Based on the scientific, rather than NEWS reports, ENMD is not worth over $20. in comparison with it's competitors at this stage of development. I am not trying to short this stock since the limited float can, and likely will, result in a temporary squeeze. I do expect wild fluctuations in price and trading to fall back into the under l00,000 shares a day volume with prices around $20 within three months. Investors just do not have enough patience to hold on for the minimum of one to two years before clinical studies can provide data on human subjects! If this stock does move up close to $60 on a short squeeze I may reconsider my decision & short trade on a daily basis!